Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
Acquiring Company
Bain Capital Private Equity
Acquired Company
Nucleus Network
MelbourneProfessional ServicesBiotechnologyHealth CareMedicalDescription
Bain Capital is nearing a binding offer deadline to acquire Nucleus Network for $1 billion. The firm has outpaced competitors, including Boyu Capital and IQVIA, in the sale process. This acquisition underscores Bain Capital's strategy in the healthcare sector. Nucleus Network specializes in clinical trials and research services.
Fundz sees it the moment Bain Capital Private Equity makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Nucleus Network?
Nucleus Network was acquired by Bain Capital Private Equity. The deal was reported on September 29, 2026. Bain Capital Private Equity has partnered closely with management teams to provide the strategic resources that build great companies and help them thrive since its founding in 1984. Bain Capital Private Equity is privately held and operates in Professional Services.
When did Bain Capital Private Equity acquire Nucleus Network?
Bain Capital Private Equity's acquisition of Nucleus Network was reported on September 29, 2026. Bain Capital is nearing a binding offer deadline to acquire Nucleus Network for $1 billion. The firm has outpaced competitors, including Boyu Capital and IQVIA, in the sale process. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Nucleus Network do?
Nucleus Network is a leading clinical trials organization based in Australia. They provide services to support clinical research for pharmaceuticals and biotechnology companies. It is privately held, operating in Biotechnology, and is based in Melbourne.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick. $29 a month, billed annually, and if it does not pay for itself in a year we refund it.
5 screens from a live account. No signup.